The simultaneous inhibition of ICOS and CD28 signaling, achieved through the use of inhibitors like Acazicolcept, has proven effective in reducing inflammation and slowing the progression of RA and psoriatic arthritis (PsA) [31]. The gene discussed is CD28; the disease is psoriatic arthritis.